ClinicalTrials.gg
RecruitingNCT07176182Updated May 26, 2026

Clinical Trial of Neoadjuvant mFOLFOX Plus Alvenor for LARC Patients With High YWHAB Expression

A Phase 2 interventional study of mFOLFOX regimen combined with Citrus Flavone Tablets (Alvenor) neoadjuvant treatment group and mFOLFOX regimen neoadjuvant therapy group in Rectal Cancer Patients, Rectal Cancer Stage II and Rectal Cancer Stage III, sponsored by Sixth Affiliated Hospital, Sun Yat-sen University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-26.

Sponsored by Sixth Affiliated Hospital, Sun Yat-sen University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
236
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Rectal Neoplasms by Sixth Affiliated Hospital, Sun Yat-sen University — 27 open to participants now, 27 under way, 3 of them phase 3. Rectal Neoplasms · Sixth Affiliated Hospital, Sun Yat-sen University.

Planned enrollment
8th of 26
236 · median 100
Started
2026
with 5 others
Phase 2
13 of 41
10 open now
Primary completion
2031-03
later than 26 of 26 live
Registered
34th of 41
by date

Among the 41 studies in Rectal Neoplasms by Sixth Affiliated Hospital, Sun Yat-sen University, this one is the 8th largest by planned enrollment of the 26 interventional ones that give a count, is one of 6 that started in 2026, is one of 13 in phase 2, reaches primary completion later than 26 of the 26 other live ones, and was the 34th registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

27 of the 41 studies in Rectal Neoplasms by Sixth Affiliated Hospital, Sun Yat-sen University are open now, in 1 country. Recruiting first, the newest first:

21 more — sign in →

By country, each count listing its studies:

All 27 open studies →

Where they have run

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Rectal Neoplasms by Sixth Affiliated Hospital, Sun Yat-sen University, or all of them as a file.
02

Study summary

This study is a prospective, multicenter, open-label, randomized controlled Phase II clinical trial enrolling patients with locally advanced rectal cancer who tested positive for YWHAB (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase-activating protein β) prior to surgery. The trial aims to evaluate the efficacy of combining the mFOLFOX chemotherapy regimen with citrus flavonoid tablets (Aimilang) for neoadjuvant (preoperative) treatment.

Treatment Regimen 4-6 cycles preoperatively, with each cycle lasting 14 days.

Translated with DeepL.com (free version)

Oxaliplatin: 85 mg/m² via 180-minute intravenous infusion on Day 1.

Leucovorin: 400 mg/m² via 120-minute intravenous infusion on Day 1.

5-Fluorouracil: 2400 mg/m² via continuous intravenous infusion over 46 hours.

Citrus flavonoid tablets (Aimailang) : 500 mg orally twice times daily (Days 1-14), administered with or without the chemotherapy regimen (depending on group assignment).

Key Trial Design Features Dose Adjustments: Permitted during the trial based on patient tolerance.

Discontinuation Criteria:

Patients with disease progression during neoadjuvant therapy will cease study treatment and proceed to surgery or alternative therapies per local guidelines.

Surgery may be initiated early if patients cannot tolerate the planned 6 cycles of neoadjuvant therapy.

Patients receiving non-protocol anticancer therapies preoperatively will be withdrawn from the study.

Postoperative Management:

Post-treatment plans (e.g., continuation of mFOLFOX + Aimailang) are determined by the investigator.

Control Group Restriction: Patients in the control arm are not permitted to self-administer citrus flavonoid tablets (Aimailang) during the trial. Any requirement for this medication must be discussed with the treating physician, who will decide on alternative therapies or trial withdrawal.

Read the detailed description

This study plans to conduct a prospective, multicenter, open-label, randomized controlled Phase II clinical trial: Endoscopic biopsy specimens from patients with locally advanced rectal cancer will undergo YWHAB immunohistochemical staining to identify those with high YWHAB expression. These patients will be randomly assigned to receive neoadjuvant therapy with either mFOLFOX alone or mFOLFOX combined with citrus flavonoid tablets (Aimailang). Following completion of 4-6 cycles of neoadjuvant chemotherapy, patients will undergo preoperative assessment by the attending physician and tumor resection performed by a specialized colorectal surgical team. This study aims to evaluate the efficacy (tumor downstaging rate, 3-year disease-free survival, overall survival, tumor regression grade [TRG], etc.) and safety (drug-related adverse reactions, etc.) of mFOLFOX combined with citrus flavonoid tablets (Aimailang) neoadjuvant therapy in patients with locally advanced rectal cancer exhibiting high YWHAB expression. Building upon the team's prior basic/translational research, animal studies, and clinical safety data for citrus flavonoid tablets (Aimailang), this study holds promise to enhance treatment outcomes for patients with locally advanced rectal cancer exhibiting high YWHAB expression, thereby benefiting a greater number of patients.

03

Conditions studied

  • Rectal Cancer Patients
  • Rectal Cancer Stage II
  • Rectal Cancer Stage III

Browse trials for

Keywords

  • Neoadjuvant Therapy
  • mFOLFOX6
  • Citrus Flavonoid Tablets (Aimailang)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria

  1. Histopathologically confirmed rectal adenocarcinoma; all other histologic subtypes are excluded. Presence of hemorrhoids confirmed by colonoscopy or clinical physical examination.
  2. Radiographically measurable or clinically evaluable rectal tumor lesion; clinical pathologic stage T2N+ or T3-4aAnyN, M0. Clinical staging is determined by physical examination, contrast-enhanced chest and abdominopelvic CT, and pelvic MRI. For patients with MRI , staging is performed with contrast-enhanced pelvic CT plus transrectal ultrasound. Staging adheres to the 9th AJCC TNM Staging System (Appendix 1).
  3. Pelvic MRI confirms the tumor is not adherent to the mesorectal fascia (MRF-negative), defined as a tumor-MRF distance ≥ 2 mm (tumor distance \< 2 mm is defined as MRF involvement).
  4. ectal cancer tumor specimens demonstrate high YWHAB expression by immunohistochemistry.
  5. Age 18-75 years at the time of .
  6. (ECOG) performance status 0 or 1 (Appendix 3).
  7. No prior systemic anticancer therapy for rectal cancer, including cytotoxic chemotherapy, , molecular targeted agents, or endocrine therapy.
  8. Adequate organ function with screening laboratory parameters meeting the following criteria:

    • White blood cell count ≥ 3 × 10⁹/L
    • ≥ 1.5 × 10⁹/L
    • count ≥ 75 × 10⁹/L
    • Total ≤ 1.5 × (ULN)
    • (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN
    • Serum creatinine ≤ 1.5 × ULN
  9. Females of must have a negative serum pregnancy test within 3 days prior to initiation of study treatment and agree to use a highly effective, medically acceptable method (e.g., intrauterine device, combined oral contraceptives, barrier methods) throughout the study and for 3 months after the last study drug administration.
  10. Male patients with partners of childbearing potential must practice effective contraception during the study and for 3 months following the last study drug administration.
  11. The patient voluntarily provides written informed consent and is willing and able to comply with all scheduled study visits, treatment administration, laboratory assessments, and protocol-specified procedures.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
236 participants (estimated)

Study arms

  • Active comparator
    mFOLFOX regimen neoadjuvant therapy group

    Trial Group Description: This trial evaluates the efficacy of combining the mFOLFOX chemotherapy regimen with citrus flavonoid tablets (Aimailang) for neoadjuvant therapy (preoperative). Treatment regimen (4-6 cycles preoperatively): Each 14-day cycle includes: Oxaliplatin: 85 mg/m² intravenous infusion on Day 1, over 180 minutes Calcium folinic acid: 400 mg/m² intravenous infusion on Day 1, over 120 minutes Fluorouracil: 2400 mg/m² continuous intravenous infusion on Day 1, over 46 hours

    Drug: mFOLFOX regimen neoadjuvant therapy group

  • Experimental
    mFOLFOX regimen combined with Citrus Flavone Tablets (Alvenor) neoadjuvant treatment group

    This trial evaluated a combination regimen of mFOLFOX chemotherapy with citrus flavonoid tablets (Aimailang) for both neoadjuvant (preoperative) and postoperative adjuvant treatment. Treatment Regimen Preoperative (4-6 cycles), each 14-day cycle included. Oxaliplatin: 85 mg/m² intravenous infusion on Day 1, administered over 180 minutes. Calcium folinic acid: 400 mg/m² intravenous infusion on Day 1, over 120 minutes. 5-Fluorouracil: 2400 mg/m², continuous intravenous infusion over 46 hours on Day 1. Citrus Flavonoid Tablets (Aimailang): 500 mg, orally twice daily (Days 1-14), may be used in combination with the chemotherapy regimen or alone (depending on grouping).

    Drug: mFOLFOX regimen combined with Citrus Flavone Tablets (Alvenor) neoadjuvant treatment group

Interventions

  • DrugmFOLFOX regimen combined with Citrus Flavone Tablets (Alvenor) neoadjuvant treatment group

    The trial evaluates a regimen combining mFOLFOX chemotherapy with citrus flavonoid tablets (Alvenor) for neoadjuvant therapy (pre-surgery) and postoperative adjuvant therapy. Treatment Protocol Preoperative (4-6 cycles) and Postoperative (6-8 cycles): Each 14-day cycle includes: Oxaliplatin: 85 mg/m² via 180-minute intravenous infusion on Day 1. Leucovorin: 400 mg/m² via 120-minute intravenous infusion on Day 1. 5-Fluorouracil: 2400 mg/m² via continuous intravenous infusion over 46 hours. Citrus flavonoid tablets (Alvenor) : 500 mg orally three times daily (Days 1-14), administered with or without the chemotherapy regimen (depending on group assignment).

    Also known as: 5-Fluorouracil, Oxaliplatin, Citrus Flavone Tablets (Alvenor)

  • DrugmFOLFOX regimen neoadjuvant therapy group

    The trial evaluates a regimen combining mFOLFOX chemotherapy with citrus flavonoid tablets (Alvenor) for neoadjuvant therapy (pre-surgery) and postoperative adjuvant therapy. Treatment Protocol Preoperative (4-6 cycles) and Postoperative (6-8 cycles): Each 14-day cycle includes: Oxaliplatin: 85 mg/m² via 180-minute intravenous infusion on Day 1. Leucovorin: 400 mg/m² via 120-minute intravenous infusion on Day 1. 5-Fluorouracil: 2400 mg/m² via continuous intravenous infusion over 46 hours.

    Also known as: 5-Fluorouracil, Oxaliplatin

06

What researchers measure

Primary outcomes

  1. Tumor downstaging rate (to ypTNM stage 0-I)

    The proportion of patients with locally advanced rectal cancer who, after receiving neoadjuvant chemotherapy with mFOLFOX or mFOLFOX plus Citrus flavonoid tablets (Aimailang), were downstaged to ypTNM stage 0-I based on postoperative surgical specimens.

    Time frame: Perioperative,2 weeks after surgery

Secondary outcomes

  1. Three-year disease-free survival

    Disease-free survival (DFS) was defined as the proportion of patients who, from the time of randomization until the end of year 3, did not experience any of the following events: disease progression; macroscopic or microscopic residual tumor after surgery; local recurrence; distant metastasis; or death from any cause, whichever occurred first.

    Time frame: through study completion, an average of 3 year

  2. Overall survival

    Overall survival (OS) was defined as the time from randomization to death from any cause.

    Time frame: through study completion, an average of 5 year

  3. tumor regression grade (TRG)

    TRG 0 indicates no residual tumor cells; TRG 1 indicates single cells or small groups of cells; TRG 2 indicates residual cancer with a desmoplastic response; and TRG 3 indicates minimal evidence of tumor response.

    Time frame: Perioperative,2 weeks after surgery

  4. Rate of Treatment-Related Adverse Events (Grade 3 or Higher)

    Treatment-related adverse event rate (Grade ≥3): Refers to grade 3 or higher adverse drug reactions determined to be related to the investigational antineoplastic drug/treatment in clinical trials, excluding nonspecific infusion reactions.

    Time frame: through study completion, an average of 1 year

  5. Complete response (CR) rate

    The proportion of patients with complete response (CR) after surgery. Complete response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm.

    Time frame: Perioperative,2 weeks after surgery

  6. Partial response (PR) rate

    The proportion of patients with partial response (PR) after surgery. Partial response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Perioperative,2 weeks after surgery

  7. Stable disease (SD) rate

    The proportion of patients with stable disease (SD) after surgery. Stable disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

    Time frame: Perioperative,2 weeks after surgery

  8. Progressive disease (PD) rate

    The proportion of patients with progressive disease (PD) after surgery. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (including the baseline if that is the smallest), with an absolute increase of at least 5 mm, or the appearance of one or more new lesions.

    Time frame: Perioperative,2 weeks after surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Mar 2031, 60 months after the start.

Of 229 non-industry phase 2 interventional studies under Rectal Neoplasms, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 80. This study's planned 60 months is above that.

Counting every sponsor, half of 243 studies reached it within 46 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2025
First posted
Sep 16, 2025
StartActual
Mar 20, 2026
Primary completionEst.
Mar 20, 2031
CompletionEst.
Mar 20, 2031
Last update
May 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07176182
Collaborators
Guangzhou First People's Hospital, Zhujiang Hospital, The First Affiliated Hospital of Guangzhou Medical University, Guangdong Provincial People's Hospital, Fujian Provincial Hospital, The Third Affiliated Hospital of Guangzhou Medical University
Responsible party
Sponsor
First posted
Sep 16, 2025
Start date
Mar 20, 2026
Primary completion
Mar 20, 2031 (estimated)
Completion
Mar 20, 2031 (estimated)
Last update
May 26, 2026

Study contacts

Tuo Hu, M.D./Ph.D
Contact
hutuo3@mail.sysu.edu.cn
+86 13763385541
Xiaosheng He, M.D./Ph.D
principal investigator · Sixth Affiliated Hospital, Sun Yat-sen University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion